热景生物连续两年亏损，实控人频繁减持

Group 1 - The core viewpoint of the article highlights that 热景生物, the first listed company in the IVD sector on the Sci-Tech Innovation Board, has experienced a significant decline in revenue and profitability following the peak of COVID-19 testing, leading to its first annual loss in 2024 [2] - In the latest performance report, the company reported a revenue of 408 million yuan, a year-on-year decrease of 20.2%, and a net profit attributable to shareholders of -211 million yuan, a decline of 10.22% [2] - The company attributed its performance pressure to factors such as asset impairment losses, increased R&D investment, and losses from external investments, alongside industry policy impacts like price reductions and decreased demand [2] Group 2 - In the context of ongoing losses, the company's controlling shareholder and related parties have reduced their holdings multiple times, cashing out over 700 million yuan through share reductions [3] - As of January 31, the company repurchased nearly 904,100 shares, accounting for 0.98% of its total share capital, at a cost of approximately 150 million yuan [3] - The company's stock price has dropped by 21.79% year-to-date as of February 27, reaching a new low of 123.71 yuan, despite a nearly 162% increase in stock price over the previous year [3] Group 3 - Analysts from 东吴证券 express optimism about the company's innovative pipeline in the cardiovascular field, highlighting potential in its subsidiaries' drug development [4] - The company has identified targets and produced pipelines in oncology, neurology, and cardiovascular areas, with unique antibody products that differentiate from competitors [4] - The subsidiaries are working on various innovative drug platforms, including a targeted small nucleic acid platform and dual-antibody drugs for cancer treatment [4]